Today, LGC announced changes to its executive leadership team to align its operating model and growth plans. These changes follow recent strong trading performance and further strategy endorsement by Cinven and Astorg, LGC’s new shareholders.
Effective 1st July 2020, Euan O’Sullivan will become Chief Operating Officer of LGC, reporting to Tim Robinson, CEO. In his new role, Euan will be responsible for leading all of LGC’s divisions. Reporting to Euan:
- Jon Yeung will become Managing Director of Standards
- Michael Sweatt continues as Executive Vice President & General Manager of Clinical Diagnostics (previously part of Standards)
- Mark Dearden will become Managing Director of Genomics, following the departure of Brian Kim.
Tim Robinson, CEO LGC, said: “LGC’s business continues to grow strongly with increasing coherence between our product lines and customers. This has been evident through the current COVID-19 pandemic, where teams across many of our operational sites have been working together to deliver innovative, integrated solutions to our customers globally. The appointments announced today bolster our ability to support our customers with the full range of existing capability, and augment and strengthen the existing leadership team that has delivered value to all stakeholders over many years.”